SCHEMBL16089692

SCHEMBL16089692

COc1cc2c(cc1OC)CN(C(=O)c1cccc(C)c1)CC2

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.73
KMT2A Q03164 3/20 0.67
MEN1 O00255 2/20 0.67
PDE4B Q07343 6/20 0.64
MAPT P10636 2/20 0.63
LMNA P02545 2/20 0.63
KDM4E B2RXH2 1/20 0.61
ALOX15 P16050 1/20 0.61
HSD17B10 Q99714 1/20 0.61
PKM P14618 1/20 0.61
CA1 P00915 1/20 0.61
CA2 P00918 1/20 0.61
CA7 P43166 1/20 0.61
CA9 Q16790 1/20 0.61
CA14 Q9ULX7 1/20 0.61
ABCB1 P08183 1/20 0.60
ALDH1A1 P00352 3/20 0.60
GAA P10253 1/20 0.60
MDM2 Q00987 1/20 0.60
PDE4D Q08499 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7893969 0.87 KMT2A (0.85) MAPK1KMT2AMEN1PDE4BMAPT
SCHEMBL30914579 0.86 MAPK1 (0.71) MAPK1KMT2AMEN1PDE4BMAPT
SCHEMBL30267796 0.86 PDE4B (0.80) MAPK1KMT2AMEN1PDE4BMAPT
SCHEMBL7894613 0.86 PDE4B (0.80) MAPK1KMT2AMEN1PDE4BMAPT
SCHEMBL7894615 0.86 MAPK1 (0.71) MAPK1KMT2AMEN1PDE4BMAPT
SCHEMBL30267843 0.86 PDE4B (0.80) MAPK1KMT2AMEN1PDE4BMAPT
SCHEMBL5125288 0.83 KMT2A (0.68) MAPK1KMT2AMEN1PDE4BMAPT
SCHEMBL12846718 0.83 HPGD (0.71) KMT2AMEN1LMNAALOX15ALDH1A1
SCHEMBL30914581 0.82 MAPK1 (0.65) MAPK1KMT2AMEN1PDE4BMAPT
SCHEMBL5127400 0.82 KMT2A (0.67) MAPK1KMT2AMEN1PDE4BMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230145822-A1 SMALL MOLECULES INDUCING THE DEGRADATION OF THE CELLULAR PRION PROTEIN FONDAZIONE TELETHON (IT) 2023-05-11 US disclosed
US-20140275529-A1 SUBUNIT SELECTIVE NMDA RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS TRAYNELIS STEPHEN F (US) 2014-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275529-A1 SUBUNIT SELECTIVE NMDA RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS GRIN1, GRIN2A, GRIN2B MAPK1 1644/4885KMT2A 2345/4885MEN1 4250/4885
US-20230145822-A1 SMALL MOLECULES INDUCING THE DEGRADATION OF THE CELLULAR PRION PROTEIN PRNP, PPIE, PPIC MAPK1 2835/4885KMT2A 4350/4885MEN1 3669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.